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Abstract
Background: Recent studies have highlighted the possible risk of neuropsychiatric adverse effects during treatment with 
lipid-lowering medications. However, there are still controversies that require a novel genetic-based approach to verify 
whether the impact of lipid-lowering drug treatment results in neuropsychiatric troubles including insomnia, depression, 
and neuroticism. Thus, we applied Mendelian randomization to assess any potential neuropsychiatric adverse effects of 
conventional lipid-lowering drugs such as statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and 
ezetimibe.
Methods: A 2-sample Mendelian randomization study was conducted based on summary statistics from genome-wide 
association studies for lipids, insomnia, depression, and neuroticism. Single-nucleotide polymorphisms located in or near 
drug target genes of HMGCR, PCSK9, and NPC1L1 were used as proxies for statins, PCSK9 inhibitors, and ezetimibe therapy, 
respectively. To assess the validity of the genetic risk score, their associations with coronary artery disease were used as a 
positive control.
Results: The Mendelian randomization analysis showed a statistically significant (P < .004) increased risk of depression after 
correcting for multiple testing with both statins (odds ratio = 1.15, 95% CI: 1.04–1.19) and PCSK9 inhibitor treatment (odds 
ratio  = 1.19, 95%CI: 1.1–1.29). The risk of neuroticism was slightly reduced with statin therapy (odds ratio = 0.9, 95%CI: 0.83–
0.97). No significant adverse effects were associated with ezetimibe treatment. As expected, the 3 medications significantly 
reduced the risk of coronary artery disease.
Conclusion: Using a genetic-based approach, this study showed an increased risk of depression during statin and PCSK9 
inhibitor therapy while their association with insomnia risk was not significant.
Keywords: statin, ezetimibe, PSCK9 inhibitor, neuropsychiatric adverse effect, Mendelian randomization
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Introduction
Statins are the main class of lipid-lowering medication that 
acts by competitively inhibiting 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGCR), a rate-limiting enzyme of the 
mevalonate pathway, which leads to downregulation of pri-
mary metabolism and results in a dose-response reduction in 
the risk of cardiovascular events (Cholesterol Treatment Trialists 
Collaboration, 2012). Statins were the most widely prescribed 
pharmacological class between 1999 and 2012, and their use is 
expected to increase after releasing the new American College 
of Cardiology and American Heart Association (ACC/AHA) guide-
lines for the management of cholesterol (Stone et  al., 2014). 
Although statins are well tolerated with an excellent safety pro-
file, severe adverse effects related to muscle and liver toxicity 
may rarely occur. Specifically, recent interest has been shifted 
toward potential risk of adverse neuropsychiatric impacts 
related to statins and other lipid-lowering medications includ-
ing PCSK9 inhibitors (Tuccori et  al., 2014; Cham et  al., 2016). 
Importantly, the accumulating evidence from medical literature 
and case reports has led the Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA; 2009)  and European Medicine 
Agency (EMA; 2009) to update the patient information leaflet for 
all statins and to include depression, sleep disturbances, and 
memory loss as potential undesirable effects.
Studies designed to investigate specific neuropsychiatric 
adverse effects have yielded conflicting results due to differ-
ences in study methodology, population, and medications types. 
For instance, randomized-controlled trials (RCTs) that assessed 
the risk of depression with statins reported conflicting results, 
ranging from a significantly high risk of depression among the 
statins group (Hyyppä et al., 2003; Morales et al., 2006) opposed 
to a significant difference between statins and control groups 
(Muldoon et al., 2000; Stewart et al., 2000) to the finding of a pro-
tective effect of statins against the risk of depression (Kim et al., 
2015). Similar inconsistency has been observed for the risk of 
sleep disturbances with a meta-analysis of 5 RCTs reporting no 
effects of statins on sleep quality (Broncel et al., 2015). However, 
based on data analysis from a postmarketing surveillance data-
base, a strong signal of potential association between statins 
use and sleep disturbances has been found (Takada et al., 2014). 
Hence, this inconsistency between studies necessitates the use 
of a novel approach to clarify if statins cause these neuropsychi-
atric adverse effects.
Mendelian randomization (MR) is an alternative approach 
that has been utilized to predict drug adverse effects using gen-
etic variants as instrument variable (IV) to assess the causal 
relationship of an exposure on an outcome (Bennett and 
Holmes, 2017). For detection of the unintended drug effects, MR 
study utilizes genetic variants located in the vicinity of the drug 
target gene (e.g., HMGCR) as IV for exposure to the medication 
(e.g., statins). For instance, concordant findings were reported 
between RCT studies and MR that suggested no beneficial 
effects of statins on the risk of Alzheimer’s disease (Feldman 
et  al., 2010; Benn et  al., 2017). A  recent study has reported an 
MR study assessing the risk of dementia diseases using genetic 
risk score (GRS) that reflects lowering low-density lipoprotein 
cholesterol (LDL-C) specifically through HMGCR, PCSK9, or both 
(Benn et al., 2017). The null association for these genetic scores 
suggested lack of evidence for the roles of LDL-C in the patho-
genesis of these diseases as well as pharmacological therapy 
that target HMGCR and PCSK9.
This study has aimed to construct GRSs that mimic the bio-
logical effects of inhibiting HMGCR (i.e., drug target gene of sta-
tin), PCSK9 (drug target gene of PCSK9 inhibitors), and NPC1L1 
(drug target gene of ezetimibe) as well as an overall genetically 
lower LDL-C level to find out whether any of these GRSs is asso-
ciated explicitly with risk of depression and sleep disturbances, 
as reported by MHRA and EMA reports. We have also assessed 
the association of these GRSs with the risk of neuroticism, a 
personality trait that is characterized by easily experiencing 
negative emotions such as anxiety and fear. HMGCR, PCSK9, and 
NPC1L1 GRS association with coronary artery disease (CAD) was 
used as a positive control.
Methods
Ethical Approval
This study used publically available summary results from 
genome-wide association studies (GWAS), which exempted the 
requirement of ethical approval. Ethical approval for the ori-
ginal studies was mentioned in the source studies. This present 
research adhered to the Declaration of Helsinki.
Study Population
Summary statistics obtained from the GWAS database were 
utilized for this study. In regards to statins effects, the Global 
Lipid Genetics Consortium (GLGC) summary results were used 
to estimate the reduction in LDL-C due to genetic variations as 
an instrumental variable (Willer et al., 2013). The GLGC studied 
lipid profile (high-density lipoprotein cholesterol [HDL-C], LDL-
C, triglycerides, and total cholesterol) in more than 188 000 indi-
viduals from 60 studies using a genome-wide array scan after 
adjusting for sex, age, genomic control inflation factor, and 
study-specific variables (Willer et al., 2013). Concerning insom-
nia, summary results were used from the Hammerschlag et al. 
(2017) study, which performed a GWAS in more than 113 000 
subjects from the UK BioBank Study. This GWAS focused on 
insomnia as measured by experiencing trouble falling asleep or 
waking up in the middle of the night. The participants answered 
a touch screen multiple-choice questionnaire including “Do 
you have trouble falling asleep at night or do you wake up in 
the middle of the night?” A help button showed the following 
information: “If this varies a lot, answer this question in rela-
tion to the last 4 weeks.” The participants had 4 multiple choice 
answers to choose from: “never/rarely,” “sometimes,” “usually,” 
Significance Statement
Statins and PCSK9 inhibitors are significantly associated with increased risk of depression as evident by findings of a significant 
association between genetic variants within HMGCR and PCSK9 genes that are associated with lower LDL-C and higher risk of 
depression. This finding appears to be a result of on-target effects of both medications since reduction LDL-C through other bio-
logical pathways were not associated with such side effects.
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or “prefer not to answer.” Cases were defined as participants who 
answered “usually” and controls those answered with “never/
rarely” or “sometimes.” Validation of the discriminative validity 
of this questionnaire in independent sample Netherlands Sleep 
Registry showed a good discriminative validity.
In regards to depression and neuroticism, the summary 
results were based on the Social Science Genetic Association 
Consortium (SSGAC) that performed a meta-analysis from 3 
cohorts and conducted a GWAS of major depressive disorder 
(n = 180 866) and neuroticism (n = 170 911) by combining data 
from the Psychiatric Genomics Consortium with UK BioBank 
and Genetic Epidemiology Research on Aging (Okbay et  al., 
2016). Different survey instruments and surveys were used in 
each cohort for defining each phenotype as described in the 
supplemental material of the original study. However, estimat-
ing the pairwise genetic correlations between the different 
measures used by each cohort showed a high correlation (Okbay 
et  al., 2016). Finally, summary results for CAD were based on 
the CARDIoGRAMplusC4D Consortium that conducted a meta-
analysis of 185 000 CAD cases and controls (Nikpay et al., 2015).
SNP Selection
Several single nucleotide polymorphisms (SNPs) were selected 
based on their significant association with the primary biomarker 
(i.e., LDL-C) and their genomic locations near lipid-lowering 
medication drug targets. First, a simple analysis was performed 
considering all the genetic variants that were significantly associ-
ated with LDL-C in GLGC, in which 54 variants were selected to be 
included in LDL-C GRS to assess the effect of genetically reduced 
LDL-C on each adverse effect (supplementary Table 1). Finding a 
significant association with this GRS implies that adverse effects 
may be a result of a biomarker effect rather than a specific mech-
anism effect. Second, we tested the presence of mechanism 
effects for each lipid-lowering medication by selecting genetic 
variants that are located in each class of gene-targeted drugs to 
serve as proxies for medication. For this reason, Ensembl Genome 
Browser was used to identify all genetic variants that are located 
within each gene region, including variants in HMGCR, NPC1L1, 
and PCSK9 genes (using the GRCh38.p10 Assembly) and were used 
as proxies for statins, ezetimibe, and PCSK9 inhibitors, respec-
tively (supplementary Figure 1). Remarkably, a metabolic profiling 
study found a high correlation in the metabolic profile of statins 
and rs12916 in HMGCR, which confirms the validity of this vari-
ant to investigate the causal molecular effects of HMGCR inhibi-
tion (Würtz et al., 2016). From all the identified variants in each 
gene, only variants that are significantly associated with LDL-C 
were considered as candidate proxies for each medication class, 
and then their summary results were also extracted from each 
outcome GWAS (Willer et  al., 2013; Nikpay et  al., 2015; Okbay 
et al., 2016; Hammerschlag et al., 2017). To select only SNPs that 
are independently associated with LDL-C, an iterative exclusion 
was performed to include only SNPs in low linkage disequilib-
rium (r2 < 0.6 for all comparisons; using European population as 
a reference; supplementary Table 2). For all variants, the reported 
effect size was oriented to the allele associated with a decreased 
lipid fraction and expressed in 1 SD of reduced lipid fraction per 
allele. The same methods were applied to other secondary lipid 
fractions (HDL, total cholesterol, and triglycerides; supplemen-
tary Tables 3–5).
Statistical Analysis
All the statistical analyses were performed by 2-samples MR using 
inverse-variance weighted (IVW) methods with uncorrelated 
variants (Burgess et al., 2015). For all the selected genetic variants, 
the effect estimates of each variant on outcome were regressed 
on its effect on LDL-C. The estimates were then pooled using a 
random meta-analytic model to produce a summary measure of 
the effect of genetically reduced LDL-C on outcome risk. To check 
for the presence of pleiotropy that could bias the MR estimates 
(i.e., sensitivity analysis), we applied MR-Egger regression and 
weighted median methods (Bowden et  al., 2015, 2016). Briefly, 
the MR regression utilizes the Egger regression method that is 
traditionally applied in meta-analysis literature review to check 
for publication bias (Egger et al., 1997). In this method, the SNP 
effect on LDL-C is plotted against its effect on the outcome, and 
the presence of pleiotropy is evident if the intercept is signifi-
cantly distinct from the origin (Bowden et al., 2015). Importantly, 
this method can provide unbiased estimates even if all the 
chosen SNPs are invalid (Bowden et al., 2015). Furthermore, the 
presence of pleiotropy was assessed by performing a confirma-
tory MR analysis using the weighted median approach, which is 
assumed to provide unbiased estimates as long as up to 50% of 
the total weight comes from variants without pleiotropic effects 
(Bowden et  al., 2016). Compared with the MR-Egger regression 
method, the weighted median is more robust to violation of IV 
assumptions and substantially improves precision. Hence, we 
utilized both methods as sensitivity analyses to assess whether 
pleiotropy had influenced our results (Bowden et al., 2016). All 
analysis were performed using the “TwoSampleMR” package for 
the R Statisical software platform. The significant association 
was considered after correcting for multiple testing (P <  .0031; 
0.05/16 comparisons).
Results
The Impacts of Lipid Biomarkers with 
Neuropsychiatric Adverse Effects (Testing the 
Presence of Biomarker Effects)
The association between LDL-C GRS, each neuropsychiatric 
adverse effects, and CAD showed a significant association 
with CAD only after correcting for multiple testing (P < .0031) 
(Table 1; Figure 1). Each 1-SD reduction in LDL-C was associ-
ated with a 36% reduction in CAD (OR = 0.64, 95%CI: 0.55–0.73). 
Risk of CAD was also proportionally associated with total cho-
lesterol and triglycerides and inversely associated with HDL-C 
(supplementary Tables  6–8). None of the 3 neuropsychiatric 
adverse effects (i.e., insomnia, depression, and neuroticism) 
were significantly associated with an LDL-C level, nor with 
any of the other lipid fractions. Heterogeneity was tested by 
Cochran’s Q statistics indicated no apparent heterogeneity 
in the estimates, except for CAD (P = 2.73E-13). The slope of 
MR-Egger was consistent with the absence of directional plei-
otropy, suggesting the validity of the IV assumptions in all the 
analyses, as evident by intercept that is insignificantly differ-
ent from 0 (Table 1). The results obtained from the weighted 
median methods further confirmed the results of the IVW 
method (supplementary Figure  2). The association of the 4 
GRSs with the other HDL-C, TG, and TC are shown in supple-
mentary Figures 3–5.
The Impact of Lipid-Lowering Drug Target Genetic 
Variants on Neuropsychiatric Adverse Effects 
(Testing the Presence of Specific Mechanisms Effects)
The association of lowering LDL-C specifically by the GRS of 
the 3 lipid-lowering drug target genes (i.e., HMGCR, NPC1L1, 
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and PCSK9) showed a significant reduction in the risk of CAD 
(Table  1; Figure  1), confirming the validity of using CAD as a 
positive control for each drug proxy GRS. Specifically, the risk of 
CAD was reduced by 35%, 43%, and 31% with statins, ezetimibe, 
and PSCK9 inhibitors, respectively. The association of these 
GRSs with the 3 neuropsychiatric adverse effects showed 
an increased risk of depression with both statins and PCSK9 
inhibitors by 12% (OR = 1.12, 95%CI: 1.04–1.18, P = .0011) and 19% 
(OR = 1.19, 95%CI 1.11–1.27, P = .00002). The risk of neuroticism 
was slightly reduced with statins treatment with a nominal P 
value (OR = 0.9, 95%CI 0.83–0.97, P = .008). No significant neuro-
psychiatric adverse effects were associated with the GRS of 
NPC1L1, and sensitivity analysis showed no evidence of het-
erogeneity or directional pleiotropy in all the analyses, as evi-
dent by very close to zero MR-Egger intercept and insignificant 
Cochran’s Q statistics.
Discussion
This present MR study has provided unique evidence of the 
increased risk of depression during statin and PSCK9 inhibi-
tor therapy as demonstrated by the significant association of 
depression with genetic inhibition of HMGCR and PCSK9. We 
showed that each 1-SD reduction (equal to 38 mg/dL) in LDL-C 
by GRSs of HMGCR and PCSK9 conferred 12% and 19% increased 
risk of depression, respectively. The validity of the tested genetic 
scores was established by finding statistically significant reduc-
tion in the risk of CAD with genetically lower level of LDL-C, as 
expected and reported by previous studies (Ference et al., 2012; 
White et al., 2016), which were also documented in several RCTs 
with lower risk of CAD after treatment with statins (LaRosa 
et al., 1999), PCSK9 inhibitors (Raal et al., 2014), and ezetimibe 
(Cannon et al., 2015). The null association between depression 
Table 1. MR Analysis of LDL-C and Genetic Proxies for Lipid Therapy with Neuropsychiatric Adverse Effects and CAD
Genetic Score MR Method
Depression Neuroticism Insomnia Coronary Artery Disease
β
(95% CI) P
β
(95% CI) P
β
(95% CI) P
β
(95% CI) P
LDL-C IVW 0.008
(-0.02–0.03)
.51 -0.1
(-0.03–0.01)
.37 -0.01
(-0.06–0.04)
.72 -0.44
(-0.53–-0.35)
9.82E-22
Weighted median 0.001 .99 0.002
(-0.03–0.003)
.91 -0.03
(-0.11–0.04)
.39 -0.45s
(-0.53–-0.36)
2.67E-25
MR-Eggera 0.003
(-0.04–0.04)
.99 -0.001
(-0.002–0.002)
.64 -0.02
(-0.09–0.06)
.66 -0.56
(-0.70–-0.41)
4.76E-10
Interceptb 0.0006
(-0.002–0.003)
.64 -0.001
(-0.002–0.002)
.91 0.001
(-0.004–0.005)
.78 0.009
(0.0003–0.02)
.05
HMGCR IVW 0.11
(0.04–0.18)
1.15E-03 -0.1
(-0.18–-0.03)
.008 -0.13
(-0.33–0.07)
.21 -0.43
(-0.62–-0.23)
1.89E-05
Weighted median 0.11
(0.03–0.18)
3.01E-03 -0.1
(-0.18–-0.02)
.02 -0.13
(-0.34–0.08)
.23 -0.42
(-0.63–-0.21)
1.06E-04
MR-Eggera 0.04
(-0.49–0.56)
.92 0.1
(-0.31–0.5)
.72 -0.21
(-1.36–0.94)
.78 -0.76
(-1.84–0.33)
.4
Interceptb -0.005
(-0.03–0.04)
.828 -0.013
(-0.04–0.02)
.5 0.005
(-0.07–0.08)
.91 0.022
(-0.048–0.091)
.65
NPC1L1 IVW 0.1
(-0.03–0.22)
.12 0.02
(-0.15–0.11)
.79 -0.23
(-0.52–0.06)
.11 -0.57
(-0.87–-0.26)
2.58E-04
Weighted median 0.09
(-0.06–0.23)
.23 0.02
(-0.17–0.13)
.79 -0.22
(-0.55–0.12)
.21 -0.57
(-0.94–-0.21)
2.16E-03
MR-Eggera 0.07
(-0.58–0.72)
.85 -0.04
(-0.56–0.65)
.91 -0.15
(-1.59–1.3)
.86 0.06
(-1.43–1.54)
.95
Interceptb 0.001
(-0.02–0.03)
.939 0.002
(-0.03–0.02)
.87 -0.003
(-0.06–0.05)
.92 -0.024
(-0.079–0.031)
.49
PCSK9 IVW 0.17
(0.09–0.26)
2.61E-05 0.14
(-0.78–0.5)
.75 0.02
(-0.1–0.13)
.78 -0.37
(-0.59–-0.15)
9.98E-04
Weighted median 0.16
(0.06–0.26)
2.02E-03 0.03
(-0.12–0.06)
.49 0.04
(-0.09–0.16)
.54 -0.47
(-0.66–-0.27)
3.36E-06
MR-Eggera -0.3
(-1.05–0.46)
.58 0.03
(-0.11–0.04))
.38 0.05
(-0.12–0.22)
.61 -0.56
(-0.86–-0.26)
.07
Interceptb 0.028
(-0.02–0.07)
.433 -0.006
(-0.03–0.04)
.8 -0.005
(-0.02–0.01)
.62 0.019
(-0.005–0.04)
0.25
Abbreviations: CAD, coronary artery disease; IVW, inverse-variance weighted; LDL-C, low-density lipoprotein cholesterol; MR, Mendelian ran-
domization; Q pval, P value. 
Estimates are in log(odds ratio) for the effect of 1-SD increase in (LDL-C); all SNPs were oriented to the LDL-C decreasing allele.
Summary statistics are based on genome-wide association studies (GWAS) from Social Science Genetic Association Consortium (SSGAC) for 
depression and neuroticism [PMID: 27089181], from Hammerschlag et al. GWAS for insomnia [PMID: 28604731], and from the CARDIoGRAMplusC4D 
for CAD.
Multiple testing is correcting P value equal to (0.05/12 = .0041). Significant P values are in bold.
aMR-Egger is considered a sensitivity test; insignificant P value does not contradict the conventional estimates from IVW.
bMR-Egger intercept is the average pleiotropic effect of genetic variants included in the analysis, if the value of the intercept is significantly dif-
ferent from zero, then the conventional MR estimate is biased (either presence of directional pleiotropy, violation of MR assumption, or both).
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and the overall LDL-C GRS suggests that the increased risk 
of depression is likely to be an on-target effect of statins and 
PCSK9 inhibitors (i.e., mechanism effect) rather than an off-
target effect or biomarker effect, as the aggregate reduction in 
LDL-C did not confer a higher risk of depression. Furthermore, 
this study increased the weight of evidence of the safety of the 
3 lipid-lowering drug classes on the sleep quality and reported a 
suggestive benefit of statins on reducing neuroticism.
Several studies have reported inconsistent findings regarding 
the association of depression with statins. Two RCTs performed 
by Morales et al. (2006) and Hyyppä et al. (2003) have reported 
an increased risk of depression among simvastatin groups com-
pared with placebo group. Furthermore, a case series of 12 partic-
ipants reported a temporal association between statin initiation 
and mood change that was resolved after drug discontinuation, 
suggesting a causal connection (Cham et al., 2016). Moreover, an 
increased risk of depression with statins was documented by 
one systematic review (You et al., 2013). In contrary, 2 systematic 
reviews have concluded evidence of potential beneficial effects 
of statins on mood with a possible reduction in the depressive 
symptoms (O’Neil et al., 2012; Salagre et al., 2016). Remarkably, 
Swiger et  al. (2014) have conducted a systematic review of 34 
studies and suggested that evidence for assessing such adverse 
effects using the available literature is limited and weak due to 
differences in data collection and methodology. These incon-
sistent findings were even documented in the Swedish national 
cohort study that reported a 7% reduction in the risk of depres-
sion with simvastatin but an 11% increase in the risk of depres-
sion with atorvastatin (Redlich et  al., 2014), suggesting that 
this protective effect is only with lipophilic statins. Smit et al. 
(2016) attributed this inconsistency to the finding that higher 
visit-to-visit LDL-C variability was associated with lower cogni-
tive performance and greater white matter hyperintensity that 
are independent of LDL-C level or statin treatment. Other fac-
tors that may increase the risk of neuropsychiatric side effects 
include the intensity of statin regimens and patients underline 
characteristics, such as pre-existing cognitive impairment, older 
age, and pharmacogenetics interactions (Swiger and Martin, 
2015).
Limited evidence is available to assess the risk of depres-
sion with PCSK9 inhibitors, as this class is considered as a new 
class with most of the RCTs in their early stages. Our finding 
of a significantly higher risk of depression with genetic inhibi-
tion of PCSK9 reported in this study represents a novel finding. 
Although Postmus et  al. (2013) have reported a null associa-
tion of rs11591147 of the PCSK9 gene with cognitive function, 
our study has specifically assessed the risk of depression with 
genetic inhibition of PCSK9 using 2-sample MR approach and 
unprecedented sample size (≈180 000). Clinically, the Open-
Label Study of Long-Term Evaluation against LDL Cholesterol 
1 trial has reported higher incidence of neurocognitive adverse 
events among the PCSK9 inhibitor group (0.9%) compared with 
the standard of care group (0.3%), and that incidence of these 
adverse events did not appear to be related to the LDL-C level 
during treatment (Sabatine et al., 2015). Similarly, the ODYSSEY 
LONG TERM trial reported a higher incidence of neurocognitive 
adverse events among the PCSK9 inhibitor group (1.2%) compared 
with 0.5% in the placebo group (Robinson et al., 2015). Although 
the Evaluating PCSK9 Binding Antibody Influence on Cognitive 
Health in High Cardiovascular Risk Subjects study reported no 
significant difference on cognitive function, study subjects were 
followed-up for a relatively short period (<2 years) and were not 
assessed for depressive symptoms specifically (Giugliano et al., 
2017). A  recent meta-analysis of 8 RCTs reported a possibility 
of neurocognitive impairment with the use of PCSK9 inhibitors 
as evident by findings that larger sample size RCTs with longer 
follow-up showed a 2.0-fold increase of the incidence of neu-
rocognitive adverse events (Khan et al., 2017). Importantly, the 
scarcity of the available evidence and the complexity of assess-
ing neuropsychiatric adverse effects for such medications, tak-
ing the statin experience as an example, implies that traditional 
RCTs are insufficient to settle debate given their inherent focus 
on group averages (Swiger and Martin, 2015).
The risk of insomnia has also been reported by several stud-
ies with inconsistent findings. The highest evidence came from 
the Medicines and Healthcare products Regulatory Agency 
(2009), which published a report after assessing the available evi-
dence suggesting that the use of statins is associated with sleep 
disturbance including insomnia. Also, one study that utilized 
Figure  1. Effect of lowering low-density lipoprotein cholesterol (LDL-C) medi-
cated by the 4 genetic risk scores. Circles represent the summary point esti-
mates of effect for the association between each exposure genetic risk score 
(GRS) and outcome. Bars represent the 95%CI.
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multiple approaches and postmarketing surveillance databases 
found a significant association between statin use and hypnotic 
drugs in the prescription sequence symmetry analysis, specific-
ally for lipophilic statins (Takada et al., 2014). However, a recent 
meta-analysis of 5 RCTs that used polysomnographic recording 
found no significant association between statin use and sleep 
duration, sleep efficiency, or entry into stage-1 sleep (Broncel 
et  al., 2015). Our study findings are consistent with the find-
ings of this meta-analysis and suggest that statins and other 
lipid-lowering medications have no significant adverse effects 
on sleep quality.
Neuroticism is the tendency to experience negative emo-
tions and is considered as one of the main 5-factor personality 
traits. Although Okbay et al. (2016) has reported a high genetic 
correlation between depression and neuroticism (r2 = 0.75, 
SEM = 0.027), neuroticism represents an independent trait that 
was found to be uniquely associated with pain catastrophizing 
and pain-related anxiety (Kadimpati et al., 2015), physical limi-
tations (Goodwin and Friedman, 2006), and responding to anti-
depressant (Tang et al., 2009). Importantly, the improvement of 
neuroticism with an antidepressant was independent of their 
effect on depression, suggesting that a specific pharmacologi-
cal effect plays a role that is distinct from its effect on depres-
sion (Tang et al., 2009). This study proposed a cause-correction 
hypothesis that antidepressant treatment may influence factors 
underlying neuroticism, leading to better depression treatment. 
From this perspective, a possible explanation of our findings is 
that the increased risk of depression observred with both PCSK9 
inhibitors and statins is not through neurobiological factors 
that underlie neuroticism. Moreover, Sutin et al. (2010) reported 
a suggestive association between HDL-C and neuroticism that 
was null for the other lipid fractions. Interestingly, our second-
ary analyses showed that HDL-C was only significantly associ-
ated with neuroticism for HMGCR GRS (supplementary Table 7). 
Although this association was only at nominal P value (P = .006), 
it emphasizes the need for further studies to specifically inves-
tigate these findings.
The mechanism by which HMGCR and PCSK9 variants 
increase the risk of depression is unclear. Nevertheless, a low 
level of cholesterol has been correlated with depression, pos-
sibly through deregulations in serotonin neurotransmission 
(Vevera et al., 2005). In addition, as cholesterol presents the main 
component of lipid rafts that play an essential role in regulated 
exocytosis pathways, an inhibition of neuronal cholesterol bio-
synthesis with lovastatin has been demonstrated to result in 
the impairment of synaptic vesicle release (Mailman et al., 2011; 
Egawa et al., 2016). Furthermore, a significant reduction in brain 
serotonin level was found in animal studies after simvastatin 
treatment (Thomas et  al., 2014). However, the findings of this 
study imply that this risk is on-target effects of both statins and 
PCSK9 inhibitors, supported by the null association observed 
with the GRSs of LDL-C and NPC1L1. Compared with statins, our 
MR models showed that the risk of depression is slightly higher 
and more significant with PCSK9 inhibitors, which is consistent 
with the higher reduction of LDL-C achieved by PCSK9 inhibitors 
but counter the very similar profile of risk reduction for CVD 
events (Ference et al., 2016). To explore these findings, we used 
the Genotype-Tissue Expression project database to evaluate 
further if HMGCR, PCSK9, and NPC1L1 are highly expressed in 
the specific tissue, particularly the brain and CNS (supplemen-
tary Figures 6 and 7). The Genotype-Tissue Expression database 
showed that unlike NPC1L1, both HMGCR and PCSK9 are highly 
expressed in the brain regions; HMGCR is highly expressed in 
the entire reported regions, whereas PCSK9 is highly expressed 
in regions of the cerebellar hemisphere and cerebellum only. 
The roles of these regions in emotional processing especially for 
negative emotional memories are well established (Fitzgerald 
et al., 2008; Monti et al., 2018). To determine whether the signifi-
cantly increased risk of depression with statins or PCSK9 inhibi-
tors is due to specific effects on these brain regions requires 
further studies. Specifically, animal and in vitro studies showed 
that statins decrease β-amyloid production, which has also been 
associated with depression (Friedhoff et  al., 2001; Sun et  al., 
2008). Similarly, a study in PCSK9-/- mice emphasized the impor-
tant role of PCSK9 in modulating the composition of brain lipids 
(Mannarino et al., 2018). Nevertheless, PCSK9 has been associ-
ated with several pleiotropic effects apart from their role in cho-
lesterol traffickings, such as regulation of neuronal apoptosis, 
disposal of nonacetylated intermediates of the nascent mem-
brane protein (BACE1), and degradation of other apolipoprotein 
E-binding receptors as well as possible roles in inflammation 
and immune functions (Banerjee et al., 2016; Mannarino et al., 
2018).
This study used a novel method of MR and the largest cur-
rently available sources of data on genetic association with lipid 
fractions and with the neuropsychiatric traits to assess the ques-
tion of causality of lipid-lowering medications on neuropsychi-
atric adverse effects. The MR method is assumed to provide 
robust evidence on the causal impact of intervening on the spe-
cific biological pathway since the effects of the genetic variants 
on that pathway are less likely to be confounded by environ-
mental, lifestyle, or disease-related factors operating later in life 
(Walker et al., 2017). Furthermore, the MR method is less likely 
to be affected by nongenetic confounding such as confounding 
by indication and reverse causation. This is because the genetic 
variants used as a proxy for drug exposure are germline vari-
ants, which are unlikely to be consequence of the indication. It 
is also unlikely that the outcome will change the DNA sequence 
(Mokry et al., 2015). However, Lohoff et al. (2017) reported that 
alcohol exposure is associated with a decreased PCSK9 methyla-
tion and lower gene expression. Hence, such epigenetics factors 
may confound the MR estimates if alcohol exposure is not con-
trolled for in the original study.
The strengths of this study are utilizing the MR approach 
using summary results from the largest available GWAS for 
each neuropsychiatric adverse and supporting the MR find-
ings by replicating the previous findings using CAD as a posi-
tive control. Also, the sensitivity analyses as performed by 
MR Egger and Weighted median tests support the findings of 
the conventional MR analysis. Concordant findings resulted 
from these methods implying that statins and PCSK9 inhibi-
tors may cause depression. Nevertheless, this study is limited 
by the same factors that limit most MR studies. First, despite 
the consistent findings from the different MR methods used in 
this study, we cannot rule out the possibility of residual plei-
otropy. However, this effect is most likely minimal given that 
the MR-Egger intercept was centered at the origin. Second, esti-
mates used in our analysis were based on summary results of 
population-based GWAS, and therefore these estimates may 
not be relevant to patient groups in whom particular therapy is 
indicated. Also, the genetic variants produce their effects over 
the course of the life, not like the inhibition of these molecular 
targets by short-term pharmacological therapy. Nevertheless, 
their impact is balanced by a small effect size, unlike the phar-
macological treatment that produces a larger effect size over a 
shorter period.
In conclusion, this study provided evidence based on the 
genetic proxy of lipid-lowering drug targets suggesting that 
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statins and PCSK9 inhibitors may increase the risk of depression, 
in particular through on-target inhibition of HMGCR and PCSK9. 
Ongoing clinical trials for PCSK9 should monitor depressive 
symptoms and postmarketing surveillance. Patients at higher 
risk of depression should be assessed regularly and preferably 
be prescribed alternative pharmacological classes. We also pro-
vided evidence that strengthens the weight of current evidence 
for the safety of statins, PCSK9 inhibitors, and ezetimibe lipid-
lowering medication on sleep efficiency.
Supplementary Materials
Supplementary data are available at International Journal of 
Neuropsychopharmacology (IJNPPY) online.
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